OptimizeRx CEO, William Febbo, to Speak at Bank of America 4th Annual HCIT and Digital Health Symposium Today, December 9, 2020
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.
- None.
- None.
ROCHESTER, Mich., Dec. 09, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to participate at the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10.
OptimizeRx CEO William Febbo will be a speaker on the panel, “Trends in Tech-Enabled Rx Supply Chain.” The panel will be moderated by Rajat Bhatia, a Director in Global Healthcare Investment Banking at BofA Securities, and Justin Walter, Head of Healthcare Services Investment Banking at BofA Securities.
Event attendees will include healthcare-focused Bank of America corporate and commercial clients, executives from healthcare services and digital health companies, as well as private equity, venture capital and crossover equity investors.
About OptimizeRx
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the US and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.
Company Contact
Doug Baker, CFO
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Media Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7557
oprx@cma.team
FAQ
What is OptimizeRx Corp. participating in on December 9-10, 2020?
Who will represent OptimizeRx at the Bank of America symposium?
What topics will be discussed at the panel featuring OptimizeRx's CEO?
What company ticker symbol corresponds to OptimizeRx?
What services does OptimizeRx provide?
